World Vaccine Washington 2019
During the conference, Viroclinics Biosciences’ experts will shed light on the topic “Transmission of Human Respiratory Syncytial Virus in the Immunocompromised Ferret Model”. During our presentation on April 16th, we will discuss the following topics:
- Demonstration of efficient transmission of human respiratory syncytial virus (HRSV) from immunocompromised ferrets to both immunocompromised and immunocompetent ferrets.
- Research findings were collected by applying several assays including Sequencing, PCR, Virus Culture/Titration. Furthermore, histo pathological changes of respiratory tissues from donor and contact ferrets were demonstrated by standard and immunohistochemistry.
- A high transmission rate of HRSV was found and more …
Furthermore, we will present our views on how R&D outsourcing can stimulate the innovation processes for vaccine developers. Practical case examples will be discussed and new horizons will be explored by sharing our latest insights on RSV, and other viral targets in our booth 307.
We are looking forward to sharing our latest insights with you during the World Vaccine Washington Conference.
Dr Koert Stittelaar, Director Preclinical Services
Dr Koert Stittelaar joined Viroclinics Biosciences in 2006. Previous to this he was a Postdoc at the Virology Department at Erasmus MC Rotterdam in vaccine and pathogenesis research projects including HIV, dengue and poxvirus preclinical research. Koert was trained in medical microbiology at the National Institute of Public Health and University of Utrecht working on Neisseria meningitidis-specific T cell responses. Koert defended his PhD thesis in 2001: “Vaccination against Measles” at the Erasmus University Rotterdam. His start at Viroclinics Biosciences boosted the Preclinical Service activities within the company. He gained expertise in the field of influenza virus and RSV intervention strategy research and is now mainly concerned with containment of highly pathogenic viruses, model development and project acquisition like polio virus related projects. Koert has authored many publications.
OUR LATEST NEWS
The French ministry of research and innovation approves Viroclinics Biosciences as an intermediate vendor for The French Tax Credit Incentive (Crédit d’Impôt Recherche or CIR), a tax relief measure for companies focused on Research & Development activities.
Parcom Capital has acquired the successful clinical research organisation Viroclinics Biosciences. Viroclinics believes Parcom is the perfect partner to help it realise its growth ambitions.
Viroclinics Biosciences serves as a virology contract research organization in the bio pharmaceutical community with preclinical, clinical diagnostic, assay development and clinical trial logistics services. Especially with extensive experience in clinical and...